At a glance
ClinicalIndex Comparison Record- ✓Previously untreated unresectable or metastatic pancreatic adenocarcinoma
- ✓ECOG Performance Status 0-2
- ✓Age 18 years or older
- ✓Radiographically measurable disease
- ✕Prior treatment with tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor
- ✕Warfarin anticoagulation
- ✕CNS or brain metastases
- ✕Blood pressure >150/100 mmHg
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Gemcitabine, Bevacizumab and Erlotinib in Locally Advanced and Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Erlotinib, and 1 other intervention for Pancreatic Cancer and Adenocarcinoma of the Pancreas. Completed, enrolled 32 participants across 3 sites.
Detailed Summary
The main purpose of this study is to learn whether or not the combination of gemcitabine, bevacizumab and erlotinib works in treating patients with advanced or metastatic pancreatic cancer. Bevacizumab is a new anti-cancer drug. It is an antibody that works to slow or stop cell growth in cancerous tumors by decreasing the blood supply to the tumors. It is approved by the FDA for the treatment of colorectal cancer but is still considered investigational for treating pancreatic cancer.
Study Details
Timeline
Interventions
Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.